-
Carbapenemase Transmission in CREC in Guangdong
2026-08-24
Chen and colleagues characterize carbapenemase-encoding genes, their chromosomal or plasmid locations, and their transfer potential in carbapenem-resistant Enterobacter cloacae collected from eight Guangdong teaching hospitals. The study links blaNDM-1 dominance and frequent conjugative transfer with multidrug resistance, while ERIC-PCR reveals both widespread genetic diversity and possible clonal overlap across hospital settings.
-
Apicidin Disrupts Oocyte Quality and Histone Acetylation
2026-08-24
A 2026 study identifies a mechanistic link between Apicidin exposure, impaired oocyte meiotic maturation, cytoskeletal disruption, altered histone acetylation, DNA damage, and early apoptosis. Its findings extend the toxicological interpretation of this histone deacetylase inhibitor from somatic-cell effects to female germ-cell quality, while also defining important boundaries for in vitro reproductive-risk research.
-
Rocilinostat (ACY-1215): Selective HDAC6 Inhibitor
2026-08-23
Rocilinostat, also called ACY-1215, is a selective HDAC6 inhibitor with a reported biochemical IC50 of 5 nM. Preclinical multiple myeloma studies indicate that HDAC6 inhibition can increase tumor-cell stress and strengthen responses to proteasome inhibitors such as bortezomib.
-
Honokiol for In Vitro Drug Response Assays
2026-08-22
Honokiol helps researchers separate pathway modulation, growth arrest, and cell killing in cancer and inflammation models. This workflow pairs time-resolved viability measurements with NF-κB, oxidative-stress, and angiogenesis readouts for more interpretable in vitro results.
-
(S)-(+)-Ibuprofen: From COX Biology to Translation
2026-08-22
A mechanistic and strategic guide to using (S)-(+)-Ibuprofen as a defined COX inhibitor in inflammation pathway research, pain mechanism studies, and translational assay development.
-
Isradipine (Dynacirc) Research Workflows
2026-08-21
Isradipine (Dynacirc) provides a practical L-type calcium-channel perturbation for separating vascular and neuronal calcium responses. This guide combines formulation guidance, electrophysiology, excitotoxicity assays, hypertension research applications, and troubleshooting strategies.
-
Dinaciclib–VHL Synthetic Lethality in CC-RCC
2026-08-20
Nelson and colleagues identify a synthetic-lethal relationship between Dinaciclib treatment and VHL deficiency in clear cell renal cell carcinoma. Their complementary cell-based and orthotopic patient-derived xenograft experiments indicate that Dinaciclib suppresses tumor growth, induces apoptosis, and affects both cancer stem and non-stem cell populations while showing greater protection in nonmalignant or VHL-restored cells that are not actively dividing.
-
Sodium Orthovanadate for Signaling Assays
2026-08-20
Sodium Orthovanadate helps preserve phosphorylation-dependent signals in adipocyte lysates, kinase assays, and enzyme workflows. This guide combines practical Na3VO4 handling with assay-specific controls inspired by research on PI3K/AKT/GLUT4 insulin signaling.
-
Gamma-linolenic acid: Workflow & Applications
2026-08-19
Gamma-linolenic acid (GLA) supports reproducible studies of LTB4-linked inflammation, lipid signaling, and cell death. This practical guide combines receptor, cell-based, and translational workflows with resistance-surveillance lessons from a psychiatric hospital study.
-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-08-19
The reference study identifies an epigenetic mechanism through which EBV protein LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It shows that HDAC inhibition can restore CEBPA expression and partially reverse this state in cellular and mouse xenograft models, supporting differentiation-based cancer therapy for selected solid tumors.
-
LNP Self-Replicating RNA Vaccine Storage: Key Evidence
2026-08-18
The reference study systematically examines how temperature, buffer composition, cryoprotection, and lyophilization affect lipid nanoparticle-formulated self-replicating RNA vaccines. Its central practical finding is that RNAse-free PBS containing 10% sucrose supported preservation of structure and in vivo potency at −20°C for 30 days, while lyophilization also retained bioactivity under the tested conditions.
-
Anti-Diabetic Drugs and Fracture Risk: Network Evidence
2026-08-18
This systematic review and network meta-analysis integrated randomized evidence on fracture outcomes across multiple anti-diabetic therapies in type 2 diabetes. Its main contribution is a drug-specific comparison showing statistically significant signals for trelagliptin, albiglutide, and voglibose, while most other agents—including ertugliflozin—remained statistically comparable with placebo.
-
IDO1 Inhibition Activates Tumor-Protective STAT3
2026-08-17
The reference study shows that apo-IDO1 inhibition can activate immune cells while simultaneously inducing an IL-6–JAK2/STAT3 survival program within tumor cells. Its single-cell and mechanistic analyses support combining IDO1-directed treatment with pathway-level inhibition to limit this adaptive, tumor-protective response.
-
Paclitaxel (Taxol) Workflows for Cancer Research
2026-08-17
Translate Paclitaxel’s microtubule-stabilizing activity into reproducible cell-cycle, cytotoxicity, and targeted nanomedicine assays. This guide connects free-drug experiments with the carrier-free PTX/GA@FA-HSA strategy reported for triple-negative breast cancer, while emphasizing dosing controls and troubleshooting.
-
Paroxetine Mesylate: Applied Research Workflows
2026-08-16
Paroxetine Mesylate supports controlled SERT, CYP, kinase, and translational oncology experiments rather than serving only as an SSRI reference compound. This guide presents assay-ready workflows, quantitative starting points, cross-domain interpretation, and troubleshooting strategies for reproducible research.